Fennec Pharmaceuticals vs Protagonist Therapeutics
Protagonist Therapeutics reported revenue of $46 million in fiscal 2025, about the same as Fennec Pharmaceuticals' $45 million in fiscal 2025. Fennec Pharmaceuticals' revenue fell 6.1% in its latest year, and Protagonist Therapeutics' fell 89.4%. Fennec Pharmaceuticals had an operating margin of -14.1%, against -343.6% at Protagonist Therapeutics.
Side by side
| Fennec Pharmaceuticals | Protagonist Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $45M | $46M |
| Revenue growth | −6.1% | −89.4% |
| Revenue growth a year, last 5 years | 194.9% | 10.0% |
| Gross margin | — | — |
| Operating margin | −14.1% | −343.6% |
| Net margin | −21.8% | −282.8% |
| Free cash flow | — | $56M |
| Free cash flow margin | — | 121.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 4.7% | −2.3% |
| Last close | $13.45 | $124.02 |
| P/E at the last close | — | 26.3× |
| Insider trades, last 12 months | sold $9.9 million | sold $79.5 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Fennec PharmaceuticalsProtagonist Therapeutics
Operating margin
Percent of revenue
Fennec PharmaceuticalsProtagonist Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fennec PharmaceuticalsProtagonist Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fennec Pharmaceuticals and Protagonist Therapeutics pages.